Nektar TherapeuticsNKTRNASDAQ
LOADING
|||

Analyst Sentiment

Analysts lean bullish — 69% recommend buying.

Consensus Rating
Buy
32 analysts·High coverage
69%
Rating Distribution
Strong Buy
00%
Buy
2269%
Hold
516%
Sell
516%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 219% higher.

Bear Case
$105.00
+181%
Consensus
$119.00
+219%
Bull Case
$135.00
+262%
Price Range32 analysts
Low
Consensus
High
$105.00
$135.00
Current Target
Current Price
$37.33
Upside to Target
$81.67

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 26, 2026Piper Sandler
Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data'
Target:$105.00
+188.9%from $36.35
Dec 16, 2025H.C. Wainwright
Nektar price target raised to $135 from $120 at H.C. Wainwright
Target:$135.00
+163.8%from $51.17
Dec 16, 2025Oppenheimer
Nektar price target raised to $115 from $98 at Oppenheimer
Target:$115.00
+128.0%from $50.43
Nov 24, 2025Jefferies
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies
Target:$121.00
+122.9%from $54.28
Sep 18, 2025Jefferies
Nektar price target raised to $99 from $69 at Jefferies
Target:$99.00
+68.5%from $58.74
Apr 18, 2022Mizuho Securities
Nektar & Bristol Myers Halt Their Combination Therapy Trials
Target:$6.00
+26.6%from $4.74
Mar 1, 2022J.P. Morgan
Nektar price target lowered to $17 from $24 at JPMorgan
Target:$17.00
+54.8%from $10.98
Nov 8, 2021Ladenburg Thalmann & Co.
Nektar upgraded to Buy from Hold at Benchmark
Target:$20.00
+36.5%from $14.65
May 18, 2021Goldman Sachs
Nektar assumed with a Neutral at Goldman Sachs
Target:$24.00
+32.4%from $18.13